Home » Newsletters » BioWorld

BioWorld

Aug. 7, 2003

View Archived Issues

Santarus Reports Success With SAN-05 Phase III In GI Bleeding

Santarus Inc. hit a fairly high hurdle in its SAN-05 Phase III trial, and partially unveiled early positive results. (BioWorld Today) Read More

BioSante Raises $10.3M To Fund Phase III Study Of Estrogen Gel

Latest Model Ebola Virus Vaccine Rescues Monkeys' Lives; People Version Possibly' Two Years Off

Cellegy Gets Cellegesic Back On Track With New Phase III

Correction

Other News To Note

Appointments And Advancements

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...